Risk factors for Pseudomonas aeruginosa airway infection and lung function decline in children with cystic fibrosis

Bell, 2020, The future of cystic fibrosis care: a global perspective, Lancet Respir Med, 8, 65, 10.1016/S2213-2600(19)30337-6 Cohen, 2012, Cystic fibrosis: a mucosal immunodeficiency syndrome, Nat Med, 18, 509, 10.1038/nm.2715 Proesmans, 2013, Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis, J Cyst Fibros, 12, 29, 10.1016/j.jcf.2012.06.001 Smith, 2006, Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients, Proc Natl Acad Sci U S A., 103, 8487, 10.1073/pnas.0602138103 Foundation, 2020, Cystic Fibrosis Foundation Patient Registry- 2019 Annual Data Report, Bethesda, Maryland Dehillotte, 2020, Registre français de la mucoviscidose – Bilan des données 2018, Vaincre la Mucoviscidose Zolin A OA, Naehrlich L, Jung A, van Rens J et al. ECFSPR Annual Report 2018. 2020. Crull, 2018, Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study, Clin Infect Dis, 67, 1089, 10.1093/cid/ciy215 Li, 2005, Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis, JAMA, 293, 581, 10.1001/jama.293.5.581 Heltshe, 2018, Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis, J Cyst Fibros, 17, 341, 10.1016/j.jcf.2017.10.008 Maselli, 2003, Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screening, Pediatr Pulmonol, 35, 257, 10.1002/ppul.10230 Rosenfeld, 2012, Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort, J Cyst Fibros, 11, 446, 10.1016/j.jcf.2012.04.003 Kerem, 1990, Risk factors for Pseudomonas aeruginosa colonization in cystic fibrosis patients, Pediatr Infect Dis J, 9, 494, 10.1097/00006454-199007000-00008 Green, 2010, Mutations that permit residual CFTR function delay acquisition of multiple respiratory pathogens in CF patients, Respir Res, 11, 140, 10.1186/1465-9921-11-140 Kosorok, 1998, Comprehensive analysis of risk factors for acquisition of Pseudomonas aeruginosa in young children with cystic fibrosis, Pediatr Pulmonol, 26, 81, 10.1002/(SICI)1099-0496(199808)26:2<81::AID-PPUL2>3.0.CO;2-K Wang, 2001, Early diagnosis of cystic fibrosis in the newborn period and risk of Pseudomonas aeruginosa acquisition in the first 10 years of life: A registry-based longitudinal study, Pediatrics, 107, 274, 10.1542/peds.107.2.274 Cutting, 2015, Cystic fibrosis genetics: from molecular understanding to clinical application, Nat Rev Genet, 16, 45, 10.1038/nrg3849 Li, 2014, Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities, Hum Genet, 133, 151, 10.1007/s00439-013-1363-7 Dorfman, 2011, Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosis, Pediatr Pulmonol, 46, 385, 10.1002/ppul.21372 Coutinho, 2014, TNF-alpha polymorphisms as a potential modifier gene in the cystic fibrosis, Int J Mol Epidemiol Genet, 5, 87 Emond, 2015, Exome Sequencing of Phenotypic Extremes Identifies CAV2 and TMC6 as Interacting Modifiers of Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis, PLoS Genet, 11, 10.1371/journal.pgen.1005273 Haerynck, 2012, Polymorphisms in the lectin pathway genes as a possible cause of early chronic Pseudomonas aeruginosa colonization in cystic fibrosis patients, Hum Immunol, 73, 1175, 10.1016/j.humimm.2012.08.010 Emond, 2012, Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis, Nat Genet, 44, 886, 10.1038/ng.2344 Pittman, 2011, Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease, Pediatr Pulmonol, 46, 497, 10.1002/ppul.21397 Konstan, 2007, Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis, J Pediatr, 151, 10.1016/j.jpeds.2007.03.006 van Horck, 2018, Risk factors for lung disease progression in children with cystic fibrosis, Eur Respir J, 51, 10.1183/13993003.02509-2017 Pittman, 2017, Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection, PLoS One, 12, 10.1371/journal.pone.0177215 HAS. Conférence de consensus- Prise en charge du patient atteint de mucoviscidose. 2002. HAS. Mucoviscidose: Protocole national de diagnostic et de soins pour une maladie rare. Guide - Affection de longue durée. 2017. Castellani, 2018, ECFS best practice guidelines: the 2018 revision, J Cyst Fibros, 17, 153, 10.1016/j.jcf.2018.02.006 Corvol, 2016, Translating the genetics of cystic fibrosis to personalized medicine, Transl Res, 168, 40, 10.1016/j.trsl.2015.04.008 Quanjer, 2012, Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations, Eur Respir J, 40, 1324, 10.1183/09031936.00080312 Pan, 1999, Extending the Iterative Convex Minorant Algorithm to the Cox Model for Interval-Censored Data, J Comput Graph Stat, 8, 109 Jones, 1991, Unequally spaced longitudinal data with AR(1) serial correlation, Biometrics, 47, 161, 10.2307/2532504 Bates, 2015, Fitting Linear Mixed-Effects Models Using lme4, J Stat Softw, 67, 1, 10.18637/jss.v067.i01 Pinheiro J BD, DebRoy S, Sarkar D, R Core Team. Linear and Nonlinear Mixed Effects Models. 2021. Therneau TM. A Package for Survival Analysis in R. 2021. Rosenfeld, 2003, Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management, Curr Opin Pulm Med, 9, 492, 10.1097/00063198-200311000-00008 Boelle, 2019, Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients, Hepatology, 69, 1648, 10.1002/hep.30148 Lee, 2003, Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients, J Cyst Fibros, 2, 29, 10.1016/S1569-1993(02)00141-8 Pressler, 2011, Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report, J Cyst Fibros, 10, S75, 10.1016/S1569-1993(11)60011-8 Merlo, 2007, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis, Chest, 132, 562, 10.1378/chest.06-2888 Marshall, 2005, Epidemiology of cystic fibrosis-related diabetes, J Pediatr, 146, 681, 10.1016/j.jpeds.2004.12.039 Limoli, 2016, Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic fibrosis-related diabetes and poor clinical outcomes, Eur J Clin Microbiol Infect Dis, 35, 947, 10.1007/s10096-016-2621-0 Toledano, 2019, The emerging burden of liver disease in cystic fibrosis patients: A UK nationwide study, PLoS One, 14, 10.1371/journal.pone.0212779 Corvol, 2015, Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis, Nat Commun, 6, 8382, 10.1038/ncomms9382 Earnest, 2020, Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry, Sci Rep, 10, 17421, 10.1038/s41598-020-74502-1